|
1
|
Brenner H, Rothenbacher D and Arndt V:
Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel S, Wang FH, Whiteside TL and Kasid
U: Identification of seven differentially displayed transcripts in
human primary and matched metastatic head and neck squamous cell
carcinoma cell lines: Implications in metastasis and/or radiation
response. Oral Oncol. 33:197–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kumar D, Gokhale P, Broustas C,
Chakravarty D, Ahmad I and Kasid U: Expression of SCC-S2, an
antiapoptotic molecule, correlates with enhanced proliferation and
tumorigenicity of MDA-MB 435 cells. Oncogene. 23:612–616. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
You Z, Ouyang H, Lopatin D, Polver PJ and
Wang CY: Nuclear factor-kappa B-inducible death effector
domain-containing protein suppresses tumor necrosis factor-mediated
apoptosis by inhibiting caspase-8 activity. J Biol Chem.
276:26398–26404. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Laliberté B, Wilson AM, Nafisi H, Mao H,
Zhou YY, Daigle M and Albert PR: TNFAIP8: A new effector for
Galpha(i) coupling to reduce cell death and induce cell
transformation. J Cell Physiol. 225:865–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang C, Kallakury BV, Ross JS, Mewani RR,
Sheehan CE, Sakabe I, Luta G, Kumar D, Yadavalli S, Starr J, et al:
The significance of TNFAIP8 in prostate cancer response to
radiation and docetaxel and disease recurrence. Int J Cancer.
133:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong QZ, Zhao Y, Liu Y, Wang Y, Zhang PX,
Jiang GY, Dong XJ, Cui QZ and Wang EH: Overexpression of SCC-S2
correlates with lymph node metastasis and poor prognosis in
patients with non-small-cell lung cancer. Cancer Sci.
101:1562–1569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duan D, Zhu YQ, Guan LL and Wang J:
Upregulation of SCC-S2 in immune cells and tumor tissues of
papillary thyroid carcinoma. Tumour Biol. 35:4331–4337. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Laliberté B, Wilson AM, Nafisi H, Mao H,
Zhou YY, Daigle M and Albert PR: TNFAIP8: A new effector for
Galpha(i) coupling to reduce cell death and induce cell
transformation. J Cell Physiol. 225:865–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang D, Ding Y, Luo WM, Bender S, Qian
CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH and Teh
BT: Inhibition of MAPK kinase signaling pathways suppressed renal
cell carcinoma growth and angiogenesis in vivo. Cancer Res.
68:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu Y, Guo E, Yu J, Xie Q and Chen J: High
DcR3 expression predicts stage pN2 in GC. Hepatogastroenterology.
54:2172–2176. 2007.PubMed/NCBI
|
|
14
|
Yang D, Fan X, Yin P, Wen Q, Yan F, Yuan
S, Liu B, Zhuang G and Liu Z: Significance of decoy receptor 3
(Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric
cancer. BMC Immunol. 13:282012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kleihues P and Sobin LH: World Health
Organization classification of tumours. Cancer. 88:28872000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sobin LH and Wittekind C: International
Union Against Cancer (UICC). TNM Classification of Malignant
Tumours (6th). (New Jersey). Wiley Blackwell, Hoboken. 2002.
|
|
17
|
Freundt EC, Bidere N and Lenardo MJ: A
different TIPE of immune homeostasis. Cell. 133:401–402. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun H, Gong S, Carmody RJ, Hilliard A, Li
L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X and Chen
YH: TIPE2, a negative regulator of innate and adaptive immunity
that maintains immune homeostasis. Cell. 133:415–426. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kumar D, Whiteside TL and Kasid U:
Identification of a novel tumor necrosis factor-alpha-inducible
gene, SCC-S2, containing the consensus sequence of a death effector
domain of fas-associated death domain-like interleukin-
1beta-converting enzyme-inhibitory protein. J Biol Chem.
275:2973–2978. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Migone TS, Zhang J, Luo X, Zhuang L, Chen
C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, et al: TL1A is a
TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roth W, Isenmann S, Nakamura M, Platten M,
Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A and Weller M:
Soluble decoy receptor 3 is expressed by malignant gliomas and
suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer
Res. 61:2759–2765. 2001.PubMed/NCBI
|
|
22
|
Pitti RM, Marsters SA, Lawrence DA, Roy M,
Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT,
et al: Genomic amplification of a decoy receptor for Fas ligand in
lung and colon cancer. Nature. 396:699–703. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bai C, Connolly B, Metzker ML, Hilliard
CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP and
Caskey CT: Overexpression of M68/DcR3 in human gastrointestinal
tract tumors independent of gene amplification and its location in
a four-gene cluster. Proc Natl Acad Sci USA. 97:1230–1235. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsuji S, Hosotani R, Yonehara S, Masui T,
Tulachan SS, Nakajima S, Kobayashi H, Koizumi M, Toyoda E and Ito
D: Endogenous decoy receptor 3 blocks the growth inhibition signals
mediated by Fas ligand in human pancreatic adenocarcinoma. Int J
Cancer. 106:17–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and
Kwon BS: A newly identified member of tumor necrosis factor
receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J
Biol Chem. 274:13733–13736. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song H, Lee AY, Jung H, Choi JH, Roh K, Ha
S, Kim KD, Bae KB, Kang MS, Park S, et al: A8, an anti-uPA
agonistic antibody, promotes metastasis of cancer cells via ERK
pathway. Monoclon Antib Immunodiagn Immunother. 33:312–318. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jerjees DAI, Alabdullah M, Alkaabi M,
Abduljabbar R, Muftah A, Nolan C, Green AR, Ellis IO and Rakha EA:
ERK1/2 is related to oestrogen receptor and predicts outcome in
hormone-treated breast cancer. Breast Cancer Res Treat. 147:25–37.
2014. View Article : Google Scholar : PubMed/NCBI
|
